Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha.
暂无分享,去创建一个
S. Stringer | M. Forster | G. Graham | B. Mulloy | J. Gallagher | C. Bishop
[1] K. Ottersbach,et al. Aggregation-independent modulation of proteoglycan binding by neutralization of C-terminal acidic residues in the chemokine macrophage inflammatory protein 1α , 2001 .
[2] K. Ottersbach,et al. Aggregation-independent modulation of proteoglycan binding by neutralization of C-terminal acidic residues in the chemokine macrophage inflammatory protein 1alpha. , 2001, The Biochemical journal.
[3] M. Forster,et al. Conformation and dynamics of heparin and heparan sulfate. , 2000, Glycobiology.
[4] J. Arnold,et al. For the record: Chemical modification of a variant of human MIP‐1α; implications for dimer structure , 2000 .
[5] J. Arnold,et al. Chemical modification of a variant of human MIP-1alpha; implications for dimer structure. , 2000, Protein science : a publication of the Protein Society.
[6] T. Oegema,et al. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins. , 2000, Blood.
[7] M. Krangel,et al. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta. , 1999, Journal of immunology.
[8] M. Lyon,et al. Highly Sensitive Sequencing of the Sulfated Domains of Heparan Sulfate* , 1999, The Journal of Biological Chemistry.
[9] V. Appay,et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. , 1999, The Journal of biological chemistry.
[10] T. Oegema,et al. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. , 1998, Blood.
[11] B. Lord,et al. CD34+AC133+ Cells Isolated from Cord Blood are Highly Enriched in Long‐Term Culture‐Initiating Cells, NOD/SCID‐Repopulating Cells and Dendritic Cell Progenitors , 1998, Stem cells.
[12] J. Turnbull,et al. Heparan Sulfate Oligosaccharides Require 6-O-Sulfation for Promotion of Basic Fibroblast Growth Factor Mitogenic Activity* , 1998, The Journal of Biological Chemistry.
[13] A. Howell,et al. A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy , 1998 .
[14] S. Kumar,et al. Endothelial and fibroblast cell-derived heparan sulphate bind with differing affinity to basic fibroblast growth factor. , 1998, Biochemical and biophysical research communications.
[15] D. Spillmann,et al. Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.
[16] F. Melo,et al. Assessing protein structures with a non-local atomic interaction energy. , 1998, Journal of molecular biology.
[17] A. Howell,et al. A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. , 1998, Blood.
[18] C. Power,et al. Glycosaminoglycans mediate cell surface oligomerization of chemokines. , 1997, Biochemistry.
[19] S. Stringer,et al. Specific Binding of the Chemokine Platelet Factor 4 to Heparan Sulfate* , 1997, The Journal of Biological Chemistry.
[20] B. Lord,et al. Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide. , 1997, British Journal of Cancer.
[21] M. Krangel,et al. Identification of a Glycosaminoglycan-binding Site in Chemokine Macrophage Inflammatory Protein-1α* , 1997, The Journal of Biological Chemistry.
[22] I. Lemischka. Microenvironmental regulation of hematopoietic stem cells , 1997, Stem cells.
[23] F. Ruscetti,et al. Raf‐1 Protein is Required for Growth Factor‐Induced Proliferation of Primitive Hematopoietic Progenitors Stimulated with Synergistic Combinations of Cytokines , 1997, Stem cells.
[24] J. Gallagher,et al. Molecules in focus: heparan sulphate , 1997 .
[25] S. Stringer,et al. Heparan sulphate. , 1997, The international journal of biochemistry & cell biology.
[26] R. Nibbs,et al. Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP‐1alpha by mutagenesis of the proteoglycan binding site. , 1996, The EMBO journal.
[27] David S. Goodsell,et al. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 , 1996, J. Comput. Aided Mol. Des..
[28] A. H. Drummond,et al. BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. , 1995, Blood.
[29] V. Roongta,et al. Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding. , 1995, The Biochemical journal.
[30] J. Turnbull,et al. Molecular organization of the interferon gamma-binding domain in heparan sulphate. , 1995, The Biochemical journal.
[31] A. Lander,et al. Differential binding of chemokines to glycosaminoglycan subpopulations , 1994, Current Biology.
[32] M. Lyon,et al. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. , 1994, The Journal of biological chemistry.
[33] A. Drake,et al. The effect of variation of substitution on the solution conformation of heparin: a spectroscopic and molecular modelling study. , 1994, Carbohydrate research.
[34] M. Tsang,et al. Aggregation of the chemokine MIP-1 alpha is a dynamic and reversible phenomenon. Biochemical and biological analyses. , 1994, The Journal of biological chemistry.
[35] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[36] M. Forster,et al. N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.
[37] N. Testa,et al. Haemopoiesis : a practical approach , 1993 .
[38] A. French,et al. Conformational analysis of the anomeric forms of sophorose, laminarabiose, and cellobiose using MM3. , 1992, Carbohydrate research.
[39] A. French,et al. Conformational analysis of the anomeric forms of kojibiose, nigerose, and maltose using MM3. , 1992, Carbohydrate research.
[40] T. Dexter,et al. Macrophage-inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo. , 1992, Blood.
[41] P. Quesenberry,et al. Stem cell factor induction of in vitro murine hematopoietic colony formation by "subliminal" cytokine combinations: the role of "anchor factors". , 1992, Blood.
[42] E. Wright,et al. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation , 1990, Nature.
[43] R. Linhardt,et al. Examination of the substrate specificity of heparin and heparan sulfate lyases. , 1990, Biochemistry.
[44] J. Turnbull,et al. Molecular organization of heparan sulphate from human skin fibroblasts. , 1990, The Biochemical journal.
[45] J. Loscalzo,et al. The interaction of platelet factor four and glycosaminoglycans. , 1985, Archives of biochemistry and biophysics.
[46] J. Shively,et al. Formation of anhydrosugars in the chemical depolymerization of heparin. , 1976, Biochemistry.
[47] H. Cohen,et al. Purification and binding properties of human platelet factor four. , 1976, The Journal of biological chemistry.
[48] Å. Wasteson. A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate. , 1971, Journal of chromatography.